Company news

Zevra Therapeutics, Inc. news in 2022

Zevra Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

December 20, 2022

KemPharm Announces Appointment of Christopher Posner as New Independent Director

November 28, 2022

KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)

November 17, 2022

KemPharm Reports Third Quarter 2022 Results

November 8, 2022

KemPharm to Report Third Quarter 2022 Financial Results

October 31, 2022

KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th

October 3, 2022

KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

September 27, 2022

KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 31, 2022

KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates

August 10, 2022

KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

August 8, 2022

KemPharm to Report Second Quarter 2022 Financial Results

August 3, 2022

KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference

August 1, 2022

KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting

July 25, 2022

KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion

May 31, 2022

KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline

May 14, 2022

KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates

May 11, 2022

KemPharm to Present at Multiple Upcoming Investor Conferences

May 10, 2022

KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)

May 4, 2022

KemPharm to Report First Quarter 2022 Financial Results

May 3, 2022

KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

April 18, 2022

KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates

March 29, 2022

KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference

March 23, 2022

KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial

March 20, 2022

KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)

March 15, 2022

KemPharm to Report Fourth Quarter and Full-Year 2021 Results

March 9, 2022

KemPharm Completes KP1077 Pre-IND Meeting Process with FDA

February 22, 2022

KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy

January 18, 2022

KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion

January 11, 2022

KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference

January 10, 2022

KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”

January 5, 2022

Decks in 2022